Protara Therapeutics (TARA) shares declined nearly 15% in after-hours trading on Friday, June 12, 2026. The stock had closed the regular session with a 9% gain. This marked its highest level in three months.
No new clinical data releases or major company announcements explained the after-hours selloff. Protara's most recent data update in May detailed positive 12-month results for its bladder cancer therapy, TARA-002. The company remains on track to initiate a new registrational trial for the drug in the second half of 2026.